Results after at least 52 weeks of open label treatment with ixekizumab, an anti-IL-17A monoclonal antibody, in a phase 2 study in chronic plaque psoriasis

• Book ID: 122128618
• Publisher: Elsevier Science
• Year: 2014
• Tongue: English
• Weight: 48 KB
• Volume: 70
• Category: Article
• ISSN: 1097-6787
• DOI: 10.1016/j.jaad.2014.01.757